Yana V. Belenkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yana V. Belenkaya has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Sergey S. Gordeyev
N.N. Blokhin National Medical Research Center of Oncology; Tyumen State Medical University
8 shared publications - Z. Z. Mamedli
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications Я. В. Беленькая
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
5 shared publicationsS. N. Lukmonov
N.N. Blokhin National Research Institute of Oncology
3 shared publications- Galina Yu. Kharkevich
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Kristina V. Orlova
N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessPola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.
- Open Access
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 118-125
Retroperitoneal end colostomy for prevention of parastomal hernia: single-center retrospective study
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 118-125
Open AccessRetroperitoneal end colostomy for prevention of parastomal hernia: single-center retrospective study
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.
- Open Access
- 19 November 2025
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 24 (4) , 125-137
Artificial intelligence for predicting long-term outcomes in patients with colorectal cancer (a systematic review and meta-analysis)
AIM: to evaluate the performance of artificial-intelligence algorithms in predicting long-term treatment outcomes in patients with colorectal cancer using clinical data alone to evaluate the performance of artificial-intelligence algorithms in predicting long-term treatment outcomes in patients with colorectal cancer (CRC) using clinical data alone. MATERIALS AND METHODS: a systematic search (2015–2024) was conducted in PubMed, Science Direct, MedRxiv, BioRxiv and Google Scholar. Original studies that applied machine-learning or deep-learning techniques exclusively to clinical variables for predicting CRC recurrence were included. Of 657106 records screened, 43 met the eligibility criteria; 12 were entered into a meta-analysis. Pooled area under the ROC curve (AUC), heterogeneity metrics (I², τ², Q-test), publication bias and sensitivity were assessed. Robustness was examined with a leave-one-out analysis. RESULTS: a systematic search (2015–2024) in PubMed, Science Direct, MedRxiv, BioRxiv and Google Scholar. Original studies that applied machine-learning or deep-learning techniques exclusively to clinical variables for predicting CRC recurrence were included. Of 657106 records screened, 43 met the eligibility criteria; 12 were entered into a meta-analysis. Pooled area under the ROC curve (AUC), heterogeneity metrics (I², τ², Q-test), publication bias and sensitivity were assessed. Robustness was examined with a leave-one-out analysis. CONCLUSION: AI models show promising accuracy in predicting colorectal cancer recurrence, supporting their potential utility in clinical decision-making. Nevertheless, further validation in large-scale, prospective studies is required before widespread clinical implementation.
- 19 November 2025
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 24 (4) , 125-137
Open AccessArtificial intelligence for predicting long-term outcomes in patients with colorectal cancer (a systematic review and meta-analysis)
AIM: to evaluate the performance of artificial-intelligence algorithms in predicting long-term treatment outcomes in patients with colorectal cancer using clinical data alone to evaluate the performance of artificial-intelligence algorithms in predicting long-term treatment outcomes in patients with colorectal cancer (CRC) using clinical data alone. MATERIALS AND METHODS: a systematic search (2015–2024) was conducted in PubMed, Science Direct, MedRxiv, BioRxiv and Google Scholar. Original studies that applied machine-learning or deep-learning techniques exclusively to clinical variables for predicting CRC recurrence were included. Of 657106 records screened, 43 met the eligibility criteria; 12 were entered into a meta-analysis. Pooled area under the ROC curve (AUC), heterogeneity metrics (I², τ², Q-test), publication bias and sensitivity were assessed. Robustness was examined with a leave-one-out analysis. RESULTS: a systematic search (2015–2024) in PubMed, Science Direct, MedRxiv, BioRxiv and Google Scholar. Original studies that applied machine-learning or deep-learning techniques exclusively to clinical variables for predicting CRC recurrence were included. Of 657106 records screened, 43 met the eligibility criteria; 12 were entered into a meta-analysis. Pooled area under the ROC curve (AUC), heterogeneity metrics (I², τ², Q-test), publication bias and sensitivity were assessed. Robustness was examined with a leave-one-out analysis. CONCLUSION: AI models show promising accuracy in predicting colorectal cancer recurrence, supporting their potential utility in clinical decision-making. Nevertheless, further validation in large-scale, prospective studies is required before widespread clinical implementation.
- Open Access
- 3 September 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (3) , 11-21
Changes in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma
The article presents a comparative analysis of Russian clinical recommendations on treatment of melanoma of the skin and mucous membranes during a period of 2020 and 2023, as well as foreign recommendations of N CCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) of 2025. The main debatable issues related to changes on melanoma therapy in 2025 are presented for discussion. The topic of modifying the treatment of patients with melanoma with metastases in the brain is highlighted. New treatment options for patients with metastatic and unresectable (stage IIIC–D) melanoma are discussed, as well as the neoadjuvant and adjuvant therapy options for stage II–III cutaneous melanoma. Various treatment options for patients with local stage melanoma are considered. Among other, the recommendations of 2025 are supplemented with treatment options for melanoma in children.Aim. To highlight changes in clinical guidelines for treatment of melanoma of the skin and mucous membranes for use in daily clinical practice.
- 3 September 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (3) , 11-21
Open AccessChanges in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma
The article presents a comparative analysis of Russian clinical recommendations on treatment of melanoma of the skin and mucous membranes during a period of 2020 and 2023, as well as foreign recommendations of N CCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) of 2025. The main debatable issues related to changes on melanoma therapy in 2025 are presented for discussion. The topic of modifying the treatment of patients with melanoma with metastases in the brain is highlighted. New treatment options for patients with metastatic and unresectable (stage IIIC–D) melanoma are discussed, as well as the neoadjuvant and adjuvant therapy options for stage II–III cutaneous melanoma. Various treatment options for patients with local stage melanoma are considered. Among other, the recommendations of 2025 are supplemented with treatment options for melanoma in children.Aim. To highlight changes in clinical guidelines for treatment of melanoma of the skin and mucous membranes for use in daily clinical practice.
- Open Access
- 1 November 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (4) , 18-42
Prognostic value of gene expression profiling in melanoma: a systematic literature review
Introduction. Skin melanoma, despite having similar clinical and histological characteristics, can have different prognoses. Gene expression profiling potentially allows for more accurate risk stratification of patients.Aim. To study prognostic test systems for assessing outcomes in patients with skin melanoma based on the analysis of primary tumors.Materials and methods. A systematic literature review (scoping review) was conducted in accordance with PRISMA-ScR principles. The search was performed in PubMed (2008–2024). Two independent reviewers conducted the study selection and data analysis to assess concordance. The data were presented descriptively.Results. Out of 149 identified publications, 31 studies were included in the review. The effectiveness of four test systems was evaluated, with the most frequently used being DecisionDx-Melanoma (19/31, 61.3%). This test stratifies patients by molecular classes: patients at high risk were found to have a 5.33 (±1.25) times higher likelihood of disease progression and poorer survival rates compared to lower-risk patients. No studies included data on the Russian population.Conclusions. Gene expression profiling demonstrates high accuracy in predicting outcomes for patients with skin melanoma.
- 1 November 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (4) , 18-42
Open AccessPrognostic value of gene expression profiling in melanoma: a systematic literature review
Introduction. Skin melanoma, despite having similar clinical and histological characteristics, can have different prognoses. Gene expression profiling potentially allows for more accurate risk stratification of patients.Aim. To study prognostic test systems for assessing outcomes in patients with skin melanoma based on the analysis of primary tumors.Materials and methods. A systematic literature review (scoping review) was conducted in accordance with PRISMA-ScR principles. The search was performed in PubMed (2008–2024). Two independent reviewers conducted the study selection and data analysis to assess concordance. The data were presented descriptively.Results. Out of 149 identified publications, 31 studies were included in the review. The effectiveness of four test systems was evaluated, with the most frequently used being DecisionDx-Melanoma (19/31, 61.3%). This test stratifies patients by molecular classes: patients at high risk were found to have a 5.33 (±1.25) times higher likelihood of disease progression and poorer survival rates compared to lower-risk patients. No studies included data on the Russian population.Conclusions. Gene expression profiling demonstrates high accuracy in predicting outcomes for patients with skin melanoma.
- Open Access
- 14 May 2024
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 23 (2) , 46-51
Retroperitoneal end colostomy for hernia prevention after laparoscopic abdominoperineal excision: a retrospective study
AIM: to compare the hernia rate and the post-operative morbidity in patients after retroperitoneal and traditional (direct) colostomy during laparoscopic APR.PATIENTS AND METHODS: the retrospective study included patients with rectal and anal cancer after laparoscopic APE in 2019-2022. Direct or retroperitoneal end colostomy were the surgeon’s choice. Primary endpoints were the hernia rate after ≥ 1 year by abdominal CT and post-operative morbidity (Clavien-Dindo).RESULTS: fifty patients were included in the study (30 patients with retroperitoneal colostomy and 20 patients with direct colostomy). There were no significant differences in parameters that could affect the results. Four (13.3%) vs 8 (40%) patients developed parastomal hernias in the retroperitoneal and direct colostomy group, accordingly (p = 0.045). No post-operative morbidity grade 4–5 and no other complications that could be attributed to retroperitoneal colostomy occurred. Post-operative morbidity grade 3 developed in 3 (10%) patients in the retroperitoneal colostomy group and in 1 (5%) — in the direct one (p = 0.64).CONCLUSION: retroperitoneal colostomy in laparoscopic APE may reduce the parastomal hernia rate. It is important to conduct prospective comparative studies.
- 14 May 2024
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 23 (2) , 46-51
Open AccessRetroperitoneal end colostomy for hernia prevention after laparoscopic abdominoperineal excision: a retrospective study
AIM: to compare the hernia rate and the post-operative morbidity in patients after retroperitoneal and traditional (direct) colostomy during laparoscopic APR.PATIENTS AND METHODS: the retrospective study included patients with rectal and anal cancer after laparoscopic APE in 2019-2022. Direct or retroperitoneal end colostomy were the surgeon’s choice. Primary endpoints were the hernia rate after ≥ 1 year by abdominal CT and post-operative morbidity (Clavien-Dindo).RESULTS: fifty patients were included in the study (30 patients with retroperitoneal colostomy and 20 patients with direct colostomy). There were no significant differences in parameters that could affect the results. Four (13.3%) vs 8 (40%) patients developed parastomal hernias in the retroperitoneal and direct colostomy group, accordingly (p = 0.045). No post-operative morbidity grade 4–5 and no other complications that could be attributed to retroperitoneal colostomy occurred. Post-operative morbidity grade 3 developed in 3 (10%) patients in the retroperitoneal colostomy group and in 1 (5%) — in the direct one (p = 0.64).CONCLUSION: retroperitoneal colostomy in laparoscopic APE may reduce the parastomal hernia rate. It is important to conduct prospective comparative studies.
- Open Access
- 15 March 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 9-20
Preliminary results of surgical treatment and neoadjuvant chemotherapy in upper rectal cancer
Introduction: There is a lack of information on the role of neoadjuvant chemotherapy in upper rectal cancer. The aim of our research was to investigate the role of neoadjuvant chemotherapy in upper rectal cancer treatment.Materials and methods: We conducted a retrospective cohort multicenter study to analyze the medical records of patients with upper rectal cancer from 2007 to 2020 obtained from the archive of Research Institute FSBI «N. N. Blokhin Cancer Research Center» of the Ministry of Health of Russia, A. N. Ryzhikh National Medical Research Centre for Coloproctology, Stavropol regional Clinical oncological Dispensary and Kaliningrad oncological Center. All patients were divided into 2 groups: group 1 included patients who underwent neoadjuvant chemotherapy with CAPOX as the first treatment step, and group 2 included patients who underwent upfront surgery. Primary endpoint was 3‑year disease-free survival (DFS) rate. We also estimated the pathological complete response (pCR) rate, treatment toxicity, postoperative morbidity rate (Clavien – Dindo), degree of tumor regression, local recurrence rate, distant metastases rate, 3‑year overall survival (OS) and the neoadjuvant chemotherapy completion rate.Results: 118 patients were included in the neoadjuvant chemotherapy group and 103 patients — in the surgery group. Study groups were well balanced and comparable for gender, the ASA status and the tumor differentiation grade. More patients in the neoadjuvant chemotherapy group had clinically positive lymph nodes (p = 0.002). Median follow-up period was 36 months. There were no significant differences in 3‑year OS and DFS. The local recurrence rate was 3.9 % in the surgery group versus 0 % in the neoadjuvant chemotherapy group (p = 0.046). There were no significant differences between study groups in the distant metastases rate (p = 0.293). Sixteen (13.6 %) patients had a pCR after neoadjuvant chemotherapy. The neoadjuvant chemotherapy completion rate was 91.5 %. The hematological toxicity grade 3–4 was observed in 3.3 % (4 patients), the non-hematological toxicity grade 3–4 in 3.3 % (4 patients).Conclusion: NACT has an acceptable toxicity profile, does not impede oncological treatment results, and can be used in a selected group of patients for early systemic control.
- 15 March 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 9-20
Open AccessPreliminary results of surgical treatment and neoadjuvant chemotherapy in upper rectal cancer
Introduction: There is a lack of information on the role of neoadjuvant chemotherapy in upper rectal cancer. The aim of our research was to investigate the role of neoadjuvant chemotherapy in upper rectal cancer treatment.Materials and methods: We conducted a retrospective cohort multicenter study to analyze the medical records of patients with upper rectal cancer from 2007 to 2020 obtained from the archive of Research Institute FSBI «N. N. Blokhin Cancer Research Center» of the Ministry of Health of Russia, A. N. Ryzhikh National Medical Research Centre for Coloproctology, Stavropol regional Clinical oncological Dispensary and Kaliningrad oncological Center. All patients were divided into 2 groups: group 1 included patients who underwent neoadjuvant chemotherapy with CAPOX as the first treatment step, and group 2 included patients who underwent upfront surgery. Primary endpoint was 3‑year disease-free survival (DFS) rate. We also estimated the pathological complete response (pCR) rate, treatment toxicity, postoperative morbidity rate (Clavien – Dindo), degree of tumor regression, local recurrence rate, distant metastases rate, 3‑year overall survival (OS) and the neoadjuvant chemotherapy completion rate.Results: 118 patients were included in the neoadjuvant chemotherapy group and 103 patients — in the surgery group. Study groups were well balanced and comparable for gender, the ASA status and the tumor differentiation grade. More patients in the neoadjuvant chemotherapy group had clinically positive lymph nodes (p = 0.002). Median follow-up period was 36 months. There were no significant differences in 3‑year OS and DFS. The local recurrence rate was 3.9 % in the surgery group versus 0 % in the neoadjuvant chemotherapy group (p = 0.046). There were no significant differences between study groups in the distant metastases rate (p = 0.293). Sixteen (13.6 %) patients had a pCR after neoadjuvant chemotherapy. The neoadjuvant chemotherapy completion rate was 91.5 %. The hematological toxicity grade 3–4 was observed in 3.3 % (4 patients), the non-hematological toxicity grade 3–4 in 3.3 % (4 patients).Conclusion: NACT has an acceptable toxicity profile, does not impede oncological treatment results, and can be used in a selected group of patients for early systemic control.
- Open Access
- 19 December 2023
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 30-38
Chemoradiotherapy for squamous cell carcinoma of the rectum: a retrospective propensity-score matched analysis
A lack of evidence-based data on the chemoradiotherapy (CRT) efficacy in patients with squamous cell carcinoma of the rectum (SCCR) makes further study of this topic extremely important.Aim: The aim of our research was to estimate the efficacy of CRT in patients with SCCR compared to the rectal adenocarcinoma and squamous cell carcinoma of the anal canal (SCCAC).Materials and methods: Our study was based on analysis of medical records of patients with ICD–X code C20 and ICD-O 8070 / 3, 8070 / 3.1, 80703 in a database from 2007 to 2020 obtained from the archive of Research Institute FSBI “N. N. Blokhin Cancer Research Center” of the Ministry of Health of Russia. We included patients with SCCR who received CRT as initial treatment into the experimental group. Groups with rectal adenocarcinoma and SCCAC were created using propensity-score matching 1:2 taking into account sex, age, the cN clinical stage, histological grade and tumor size. The main study endpoints were 3‑year overall survival (OS) and disease-free survival (DFS) rates, complete clinical response rate and complete clinical or pathological response rate at 6 months after CRT, local recurrence and distant metastases rates, surgery rate.Results: We included 15 patients in SCCR group and 30 patients in rectal adenocarcinoma group and SCCAC group each. There were no significant differences in parameters that could affect the prognosis. The complete clinical response was achieved in 7 (46.7 %) patients with SCCR versus 3 (10.0 %) patients with adenocarcinoma (p = 0.005) and 24 (80.0 %) patients with SCCAC (p = 0.005). The surgery rate was 26.6 % (4 patients) in SCCR group, 6.67 % (2 patients) in SCCAC group, 90 % (27 patients) in adenocarcinoma group (p < 0.001). The recurrence rate was 26.7 % (4 patients) in SCCR group versus 10.0 % (3 patients) in adenocarcinoma group (p = 0.146) and 6.7 % (2 patients) in SCCAC group (p = 0.063). The metastases rate was 26.7 % (4 patients) in SCCR group, 26.7 % (8 patients) in adenocarcinoma group (p > 0.99). In SCCAC group metastases were detected in 1 (3.3 %) patient, which was significantly different compared to the SCCR group (p = 0.019). Median follow up was 44 months. The 3‑year OS was 78.8 % in SCCR group versus 91.0 % in adenocarcinoma group (p = 0.675), and 86.3 % in SCCAC group (p = 0.953). The 3‑year OS in adenocarcinoma and SCCAC groups did not differ (p = 0.996). The 3‑year DFS was 34.7 % in SCCR group versus 55.6 % in adenocarcinoma group (p = 0.504) and 82.9 % in SCCAC group (p = 0.031). The 3‑year DFS differences in adenocarcinoma and SCCAC groups were significant (p = 0.041).Conclusions: We have obtained important data on the CRT comparative efficacy in patients with SCCR, SCCAC and rectal adenocarcinoma. The high complete clinical response rate in SCCR group makes it possible to consider the use of CRT as the main treatment method. Results of our research can be used to plan the treatment of patients with SCCR.
- 19 December 2023
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 30-38
Open AccessChemoradiotherapy for squamous cell carcinoma of the rectum: a retrospective propensity-score matched analysis
A lack of evidence-based data on the chemoradiotherapy (CRT) efficacy in patients with squamous cell carcinoma of the rectum (SCCR) makes further study of this topic extremely important.Aim: The aim of our research was to estimate the efficacy of CRT in patients with SCCR compared to the rectal adenocarcinoma and squamous cell carcinoma of the anal canal (SCCAC).Materials and methods: Our study was based on analysis of medical records of patients with ICD–X code C20 and ICD-O 8070 / 3, 8070 / 3.1, 80703 in a database from 2007 to 2020 obtained from the archive of Research Institute FSBI “N. N. Blokhin Cancer Research Center” of the Ministry of Health of Russia. We included patients with SCCR who received CRT as initial treatment into the experimental group. Groups with rectal adenocarcinoma and SCCAC were created using propensity-score matching 1:2 taking into account sex, age, the cN clinical stage, histological grade and tumor size. The main study endpoints were 3‑year overall survival (OS) and disease-free survival (DFS) rates, complete clinical response rate and complete clinical or pathological response rate at 6 months after CRT, local recurrence and distant metastases rates, surgery rate.Results: We included 15 patients in SCCR group and 30 patients in rectal adenocarcinoma group and SCCAC group each. There were no significant differences in parameters that could affect the prognosis. The complete clinical response was achieved in 7 (46.7 %) patients with SCCR versus 3 (10.0 %) patients with adenocarcinoma (p = 0.005) and 24 (80.0 %) patients with SCCAC (p = 0.005). The surgery rate was 26.6 % (4 patients) in SCCR group, 6.67 % (2 patients) in SCCAC group, 90 % (27 patients) in adenocarcinoma group (p < 0.001). The recurrence rate was 26.7 % (4 patients) in SCCR group versus 10.0 % (3 patients) in adenocarcinoma group (p = 0.146) and 6.7 % (2 patients) in SCCAC group (p = 0.063). The metastases rate was 26.7 % (4 patients) in SCCR group, 26.7 % (8 patients) in adenocarcinoma group (p > 0.99). In SCCAC group metastases were detected in 1 (3.3 %) patient, which was significantly different compared to the SCCR group (p = 0.019). Median follow up was 44 months. The 3‑year OS was 78.8 % in SCCR group versus 91.0 % in adenocarcinoma group (p = 0.675), and 86.3 % in SCCAC group (p = 0.953). The 3‑year OS in adenocarcinoma and SCCAC groups did not differ (p = 0.996). The 3‑year DFS was 34.7 % in SCCR group versus 55.6 % in adenocarcinoma group (p = 0.504) and 82.9 % in SCCAC group (p = 0.031). The 3‑year DFS differences in adenocarcinoma and SCCAC groups were significant (p = 0.041).Conclusions: We have obtained important data on the CRT comparative efficacy in patients with SCCR, SCCAC and rectal adenocarcinoma. The high complete clinical response rate in SCCR group makes it possible to consider the use of CRT as the main treatment method. Results of our research can be used to plan the treatment of patients with SCCR.
- 5 November 2023
- Published by Wiley in Colorectal Disease
- Vol. 25 (12) , 2467-2469
Laparoscopic retroperitoneal end colostomy creation – A video vignette
- 5 November 2023
- Published by Wiley in Colorectal Disease
- Vol. 25 (12) , 2467-2469
Laparoscopic retroperitoneal end colostomy creation – A video vignette
- Open Access
- 28 August 2023
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 22 (3) , 62-69
The efficacy of neoadjuvant chemoradiotherapy in signet ring cell carcinoma of the rectum: a retrospective propensity-score matched study
INTRODUCTION: there is a lack of information chemoradiotherapy (CRT) efficacy in signet ring cell carcinoma of the rectum (SRCCR). The aim of our research was to investigate the efficacy of preoperative CRT in patients with SRCCR.PATIENTS AND METHODS: we conducted a retrospective analysis of medical records from the archive of Research Institute FSBI “N.N. Blokhin Cancer Research Center” of the Ministry of Health of Russia and multicenter registry of the Russian Society of Specialists in Colorectal Cancer (RSSCC) from 2000 to 2020 and included in the study group patients with histologically confirmed primary SRCCR who received preoperative CRT. A control group with rectal adenocarcinoma was created using propensity-score matching from the institutional database 1:1 taking into account sex, age, tumor size, the cT and cN clinical stage. We estimated the rate of Dworak tumor regression grade 3-4, RECIST, 5-year overall survival (OS) and disease-free survival (DFS) rates.RESULTS: the study and control group included 22 patients each. The study group included 11 patients (50%) with cT3 and cT4 clinical stage. 10 (45,5%) patients had cT3 clinical stage and 12 (54,5%) patients had cT4 clinical stage in the control group (p = 0,763). The number of patients with cN1-2 clinical stage was 17 (77,3%) and 16 (72,7%) in the study and control group, respectively (p = 0,728). The rate of Dworak tumor regression grade 3–4 was 40,9% in the group of patients with SRCCR and 45,5% in the group of patients with rectal adenocarcinoma (p = 0,761).When assessed by RECIST scale, 9 (40,9%), 12 (54,5%) and 1 (4,5%) patients with SRCCR had partial tumor response, stabilization and progression, respectively. Partial response was observed in 18 (81,8%) patients and stabilization — in 4 (18,2%) patients with rectal adenocarcinoma (p = 0,018). Median followup was 58,8 months. The 5-year OS was 34% in the SRCCR group and 71,3% in the group with rectal adenocarcinoma (p = 0,024), and the 5-year PFS was 30,2% with SRCCR and 52,2% with adenocarcinoma (p = 0,115).CONCLUSIONS: CRT leads to comparable grade 3–4 tumor regression in SRCCR and rectal adenocarcinoma, but the objective response rate is lower. This histological subtype has significantly lower OS values.
- 28 August 2023
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 22 (3) , 62-69
Open AccessThe efficacy of neoadjuvant chemoradiotherapy in signet ring cell carcinoma of the rectum: a retrospective propensity-score matched study
INTRODUCTION: there is a lack of information chemoradiotherapy (CRT) efficacy in signet ring cell carcinoma of the rectum (SRCCR). The aim of our research was to investigate the efficacy of preoperative CRT in patients with SRCCR.PATIENTS AND METHODS: we conducted a retrospective analysis of medical records from the archive of Research Institute FSBI “N.N. Blokhin Cancer Research Center” of the Ministry of Health of Russia and multicenter registry of the Russian Society of Specialists in Colorectal Cancer (RSSCC) from 2000 to 2020 and included in the study group patients with histologically confirmed primary SRCCR who received preoperative CRT. A control group with rectal adenocarcinoma was created using propensity-score matching from the institutional database 1:1 taking into account sex, age, tumor size, the cT and cN clinical stage. We estimated the rate of Dworak tumor regression grade 3-4, RECIST, 5-year overall survival (OS) and disease-free survival (DFS) rates.RESULTS: the study and control group included 22 patients each. The study group included 11 patients (50%) with cT3 and cT4 clinical stage. 10 (45,5%) patients had cT3 clinical stage and 12 (54,5%) patients had cT4 clinical stage in the control group (p = 0,763). The number of patients with cN1-2 clinical stage was 17 (77,3%) and 16 (72,7%) in the study and control group, respectively (p = 0,728). The rate of Dworak tumor regression grade 3–4 was 40,9% in the group of patients with SRCCR and 45,5% in the group of patients with rectal adenocarcinoma (p = 0,761).When assessed by RECIST scale, 9 (40,9%), 12 (54,5%) and 1 (4,5%) patients with SRCCR had partial tumor response, stabilization and progression, respectively. Partial response was observed in 18 (81,8%) patients and stabilization — in 4 (18,2%) patients with rectal adenocarcinoma (p = 0,018). Median followup was 58,8 months. The 5-year OS was 34% in the SRCCR group and 71,3% in the group with rectal adenocarcinoma (p = 0,024), and the 5-year PFS was 30,2% with SRCCR and 52,2% with adenocarcinoma (p = 0,115).CONCLUSIONS: CRT leads to comparable grade 3–4 tumor regression in SRCCR and rectal adenocarcinoma, but the objective response rate is lower. This histological subtype has significantly lower OS values.